What is the current stock price of Mustang Bio, Inc. (MBIO)?

As of the latest market data, Mustang Bio, Inc. (MBIO) is trading at $0.70. The stock has seen a loss of -5.79% today.

Does Mustang Bio, Inc. (MBIO) pay a dividend?

Based on current data, Mustang Bio, Inc. does not have a confirmed active dividend policy.

What is the market cap of Mustang Bio, Inc.?

The current market capitalization of Mustang Bio, Inc. (MBIO) is approximately unavailable.

MBIO

Mustang Bio, Inc.·Healthcare

0.70

5.787%(−0.04)

Market Closed

0.89

26.971%(+0.19)

After Hours

Last Updated: — ET

52W L: $0.5352W H: $7.00

MBIO NEWS

thenewswire.com

Apr 1

MindBio Announces Closing of Private Placement

Vancouver, British Columbia – April 1, 2026 – TheNewswire - MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce that it has closed its previously announced upsized non-brokered private placement (the “ Offering ”) for gross proceeds of $1,437,828.87

thenewswire.com

Mar 19

MindBio Announces Upsize to Private Placement up to $1.5 Million

Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “ Offering ”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units of the Company (the “ Units ”) at a price of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit will consist of one common share of the Company (each, a “ Share ”) and one Share purchase warrant (each, a “ Warrant ”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.

defenseworld.net

Feb 27

Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)

Mustang Bio (NASDAQ: MBIO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current recommendations

thenewswire.com

Feb 18

MindBio Announces Private Placement to Raise up to $650,000

Vancouver, British Columbia - TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce it will conduct a non-brokered private placement (the “ Offering ”) to raise gross proceeds of up to $650,000 to accelerate the development of its enterprise intoxication detection solution, including the production of proprietary hardware and edge technologies for remote deployment in the mining industry.

thenewswire.com

Feb 18

MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform

Vancouver, British Columbia – TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”) , a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, today announced it has commenced development of a proprietary edge computing platform, including dedicated hardware, to enable large-scale deployment in the mining industry. The Company is working with an experienced engineering firm with expertise in hardware and sensor development to design and manufacture the Company's integrated Edge AI solution for real-time, on-device voice analysis in remote and infrastructure-limited environments. Prototype development is nearing completion, with hardware manufacturing and field-ready deployment expected in Q2 2026.

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-08-22

Beta

2.18

Websitewww.mustangbio.com↗